Non-Hodgkin’s Lymphoma and Chronic Lymphocytic Leukemia – Epidemiology – Mature Markets

Clarivate Epidemiology’s coverage of non-Hodgkin’s lymphoma (NHL) and chronic lymphocytic leukemia (CLL) comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report both the incidence and prevalence of NHL and CLL for each country, as well as annualized case counts projected to the national population.

Most patient populations are forecast over a period of 20 years for the major mature pharmaceutical markets and 10 years for the other countries covered in this report. In addition to forecasting incident and prevalent patient populations, we estimate the number of drug-treatment opportunities in specific lines of therapy in the major mature pharmaceutical markets.

Clarivate Epidemiology’s NHL and CLL forecast will answer the following questions:

  • Of all people diagnosed with NHL and CLL, how many in each of the major mature pharmaceutical markets are drug-treated?
  • How will demographic trends, such as population aging and improving life expectancy, affect the epidemiology of NHL and CLL over the forecast period?

All forecast data are available on the Clarivate Insights Platform in tabular format, with options to download to MS Excel. All populations are accompanied by a comprehensive description of the methods and data sources used, with hyperlinks to external sources. A summary evidence table generated as part of our systematic review of the epidemiological literature is also provided for full transparency into research and methods. In addition, we provide a graphical depiction of the patient flow between or within different disease states for the countries considered in this report. These patient flow diagrams are provided at the regional level, but may be requested for any specific country or forecast year.

In total, Clarivate Epidemiology forecasts 86 NHL and CLL patient populations, as follows:

  • Diagnosed first-line drug-treatable population of CLL + small lymphocytic lymphoma (SLL).
  • Diagnosed prevalent cases of diffuse large B-cell lymphoma (DLBCL) transformed from follicular lymphoma (FL).
  • Diagnosed prevalent cases of NHL.
  • Diagnosed third-line drug-treatable DLBCL population.
  • Transformed incident cases of FL to DLBCL.
  • Diagnosed incident cases of NHL.
  • Diagnosed first-line drug-treatable mantle cell lymphoma (MCL) population.
  • Diagnosed prevalent cases of FL.
  • Diagnosed incident cases of MCL.
  • … and many more (details available on request).

Note: Coverage may vary by country.

launch Related Market Assessment Reports